Yang Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yang Wu has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Kuirong Jiang
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
8 shared publications - Yi Miao
Pancreas Center, Nanjing BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, China
6 shared publications Zipeng Lu
Pancreas Center, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University
6 shared publicationsHao Yuan
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
5 shared publicationsChun Zhang
Department of General, Visceral and Transplantation Surgery, Ludwig-Maximilians-University Munich, Munich, Bayern, Germany, uni-muenchen.de
4 shared publicationsDongfang Liu
Pancreas Center, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University
4 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by Springer Nature in Nutrition Journal
- Vol. 25 (1)
Effect and safety of nutritional supplements on clinical outcomes in patients with acute pancreatitis: a systematic review and network meta-analysis
The effectiveness of nutritional supplements is controversial compared to standard supplementation in the clinical management of individuals with acute pan
- 27 February 2026
- Published by Springer Nature in Nutrition Journal
- Vol. 25 (1)
Open AccessEffect and safety of nutritional supplements on clinical outcomes in patients with acute pancreatitis: a systematic review and network meta-analysis
The effectiveness of nutritional supplements is controversial compared to standard supplementation in the clinical management of individuals with acute pan
- Open Access
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1) , e2632235
The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells
Pancreatic ductal adenocarcinoma (PDAC) exhibits pronounced desmoplasia, primarily attributed to the activation of pancreatic stellate cells (PSCs) from a quiescent state (quiescent PSCs [qPSCs]) to an activated form (activated PSCs [aPSCs]), which facilitates tumor progression and therapeutic resistance. This study investigates the potential of the vitamin D3 (VD) analog calcipotriol (Cal) to modulate this activation process and its impact on PDAC cell malignancy, with a particular focus on the thrombospondin 1/cluster of differentiation 47 (THBS1/CD47) signaling axis. Through analyzing VDR mRNA expression in aPSCs versus PDAC cells, we found that aPSCs are more responsive to VD signaling. Treatment with Cal significantly reduced aPSC activation, as evidenced by decreased α‐SMA expression and THBS1 secretion, thereby diminishing stromal support for PDAC cell proliferation, migration, and invasion. These changes were mediated by the inhibition of the THBS1/CD47 axis, highlighting a novel mechanism by which Cal disrupts the supportive tumor microenvironment. Our findings highlight the therapeutic potential of targeting aPSCs with VD analogs in PDAC, suggesting a new direction for treatments that aim to interrupt the desmoplastic reaction and thereby inhibit PDAC progression.
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1) , e2632235
Open AccessThe Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells
Pancreatic ductal adenocarcinoma (PDAC) exhibits pronounced desmoplasia, primarily attributed to the activation of pancreatic stellate cells (PSCs) from a quiescent state (quiescent PSCs [qPSCs]) to an activated form (activated PSCs [aPSCs]), which facilitates tumor progression and therapeutic resistance. This study investigates the potential of the vitamin D3 (VD) analog calcipotriol (Cal) to modulate this activation process and its impact on PDAC cell malignancy, with a particular focus on the thrombospondin 1/cluster of differentiation 47 (THBS1/CD47) signaling axis. Through analyzing VDR mRNA expression in aPSCs versus PDAC cells, we found that aPSCs are more responsive to VD signaling. Treatment with Cal significantly reduced aPSC activation, as evidenced by decreased α‐SMA expression and THBS1 secretion, thereby diminishing stromal support for PDAC cell proliferation, migration, and invasion. These changes were mediated by the inhibition of the THBS1/CD47 axis, highlighting a novel mechanism by which Cal disrupts the supportive tumor microenvironment. Our findings highlight the therapeutic potential of targeting aPSCs with VD analogs in PDAC, suggesting a new direction for treatments that aim to interrupt the desmoplastic reaction and thereby inhibit PDAC progression.
- Open Access
- 1 January 2026
- Published by Tech Science Press in Oncology Research
- Vol. 34 (2) , 1-10
Cancer-Associated Fibroblasts in Prostate Cancer: Unraveling Mechanisms and Therapeutic Implications
Prostate cancer (PCa) remains a major cause of cancer-related mortality in men, largely due to therapy resistance and metastatic progression. Increasing evidence highlights the tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), as a critical determinant of disease behavior. CAFs constitute a heterogeneous population originating from fibroblasts, mesenchymal stem cells, endothelial cells, epithelial cells undergoing epithelial–mesenchymal transition (EMT), and adipose tissue. Through dynamic crosstalk with tumor, immune, endothelial, and adipocyte compartments, CAFs orchestrate oncogenic processes including tumor proliferation, invasion, immune evasion, extracellular matrix remodeling, angiogenesis, and metabolic reprogramming. This review comprehensively summarizes the cellular origins, phenotypic and functional heterogeneity, and spatial distribution of CAFs within the prostate TME. We further elucidate the molecular mechanisms by which CAFs regulate PCa progression and therapeutic resistance, and critically evaluate emerging strategies to therapeutically target CAF-mediated signaling, metabolic, and immune pathways. By integrating recent advances from single-cell and spatial transcriptomics (ST), our objective is to provide a holistic framework for understanding CAF biology and to highlight potential avenues for stromal reprogramming as an adjunct to current PCa therapies.
- 1 January 2026
- Published by Tech Science Press in Oncology Research
- Vol. 34 (2) , 1-10
Open AccessCancer-Associated Fibroblasts in Prostate Cancer: Unraveling Mechanisms and Therapeutic Implications
Prostate cancer (PCa) remains a major cause of cancer-related mortality in men, largely due to therapy resistance and metastatic progression. Increasing evidence highlights the tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), as a critical determinant of disease behavior. CAFs constitute a heterogeneous population originating from fibroblasts, mesenchymal stem cells, endothelial cells, epithelial cells undergoing epithelial–mesenchymal transition (EMT), and adipose tissue. Through dynamic crosstalk with tumor, immune, endothelial, and adipocyte compartments, CAFs orchestrate oncogenic processes including tumor proliferation, invasion, immune evasion, extracellular matrix remodeling, angiogenesis, and metabolic reprogramming. This review comprehensively summarizes the cellular origins, phenotypic and functional heterogeneity, and spatial distribution of CAFs within the prostate TME. We further elucidate the molecular mechanisms by which CAFs regulate PCa progression and therapeutic resistance, and critically evaluate emerging strategies to therapeutically target CAF-mediated signaling, metabolic, and immune pathways. By integrating recent advances from single-cell and spatial transcriptomics (ST), our objective is to provide a holistic framework for understanding CAF biology and to highlight potential avenues for stromal reprogramming as an adjunct to current PCa therapies.
- Open Access
- 3 September 2025
- Published by Wiley in Cell Proliferation
- Vol. 58 (12) , e70125
Targeting ARPC1B + Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment
ARPC1B+ cancer stem cells (CSCs) in pancreatic cancer are identified as a subpopulation resistant to gemcitabine. In our study, drug repositioning, molecular docking, and surface plasmon resonance (SPR) technique jointly revealed that CK-636 can directly target ARPC1B protein with high affinity. In vitro cytotoxicity, ex vivo organoid cultures, in vivo xenograft and orthotopic gemcitabine-resistant pancreatic cancer model demonstrated that combination therapy of gemcitabine plus CK-636 showed a superior anti-tumor effect compared with gemcitabine monotherapy. Our study demonstrated that CK-636 can act as a rational adjuvant to overcome gemcitabine resistance in pancreatic cancer therapy.
- 3 September 2025
- Published by Wiley in Cell Proliferation
- Vol. 58 (12) , e70125
Open AccessTargeting ARPC1B + Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment
ARPC1B+ cancer stem cells (CSCs) in pancreatic cancer are identified as a subpopulation resistant to gemcitabine. In our study, drug repositioning, molecular docking, and surface plasmon resonance (SPR) technique jointly revealed that CK-636 can directly target ARPC1B protein with high affinity. In vitro cytotoxicity, ex vivo organoid cultures, in vivo xenograft and orthotopic gemcitabine-resistant pancreatic cancer model demonstrated that combination therapy of gemcitabine plus CK-636 showed a superior anti-tumor effect compared with gemcitabine monotherapy. Our study demonstrated that CK-636 can act as a rational adjuvant to overcome gemcitabine resistance in pancreatic cancer therapy.
- Open Access
- 1 March 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (3)
The cell fate regulator DACH1 modulates ferroptosis through affecting P53/SLC25A37 signaling in fibrotic disease
Background: Dachshund homolog 1 (DACH1) is widely acknowledged for its involvement in regulating diverse cell fates, but its precise regulatory mechanism in ferroptosis remains elusive. In this study, we investigated whether DACH1 modulates ferroptosis through affecting P53/solute carrier family 25 member 37 (SLC25A37) signaling in hepatic fibrogenesis. Methods: CRISPR-Cas9 system was used to knockout DACH1 in HSC to determine the effect of DACH1 on ferroptosis. Immunoprecipitation, pulldown, and mouse model of hepatic fibrogenesis were used to analyze the potential molecular mechanism of ferroptosis regulation by DACH1. Results: We found that ferroptosis inducers increased the protein expression of DACH1 by suppressing the ubiquitin-proteasome signaling. DACH1 knockout can resist ferroptosis, whereas DACH1 knockin can enhance it. Interestingly, the upregulation of DACH1 resulted in the mitochondrial translocation of p53 by inducing phosphorylation at serine 392. The mutation of serine 392 can prevent the combination of DACH1 and p53, the mitochondrial translocation of p53, and DACH1-mediated ferroptosis. Moreover, SLC25A37 was identified as a candidate target for mitochondrial p53. The binding of p53 to SLC25A37 can enhance the iron uptake capacity of SLC25A37, which may cause an overload of iron in the mitochondria and hyperactive mitochondrial electron transport chain. Knockdown of SLC25A37 can impair p53-mediated mitochondrial iron overload and ferroptosis. Furthermore, treatment with erastin can induce HSC ferroptosis and relieve fibrotic lesion damage in the mouse model of hepatic fibrogenesis. HSC-specific knockdown of DACH1, p53, and SLC25A37 can abolish the induction of HSC ferroptosis and reversal of hepatic fibrogenesis by erastin treatment. Conclusions: Our findings suggest that the DACH1/P53/SLC25A37 signaling pathway is a promising target for fibrotic disorders and reveals new regulatory mechanisms of ferroptosis.
- 1 March 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (3)
Open AccessThe cell fate regulator DACH1 modulates ferroptosis through affecting P53/SLC25A37 signaling in fibrotic disease
Background: Dachshund homolog 1 (DACH1) is widely acknowledged for its involvement in regulating diverse cell fates, but its precise regulatory mechanism in ferroptosis remains elusive. In this study, we investigated whether DACH1 modulates ferroptosis through affecting P53/solute carrier family 25 member 37 (SLC25A37) signaling in hepatic fibrogenesis. Methods: CRISPR-Cas9 system was used to knockout DACH1 in HSC to determine the effect of DACH1 on ferroptosis. Immunoprecipitation, pulldown, and mouse model of hepatic fibrogenesis were used to analyze the potential molecular mechanism of ferroptosis regulation by DACH1. Results: We found that ferroptosis inducers increased the protein expression of DACH1 by suppressing the ubiquitin-proteasome signaling. DACH1 knockout can resist ferroptosis, whereas DACH1 knockin can enhance it. Interestingly, the upregulation of DACH1 resulted in the mitochondrial translocation of p53 by inducing phosphorylation at serine 392. The mutation of serine 392 can prevent the combination of DACH1 and p53, the mitochondrial translocation of p53, and DACH1-mediated ferroptosis. Moreover, SLC25A37 was identified as a candidate target for mitochondrial p53. The binding of p53 to SLC25A37 can enhance the iron uptake capacity of SLC25A37, which may cause an overload of iron in the mitochondria and hyperactive mitochondrial electron transport chain. Knockdown of SLC25A37 can impair p53-mediated mitochondrial iron overload and ferroptosis. Furthermore, treatment with erastin can induce HSC ferroptosis and relieve fibrotic lesion damage in the mouse model of hepatic fibrogenesis. HSC-specific knockdown of DACH1, p53, and SLC25A37 can abolish the induction of HSC ferroptosis and reversal of hepatic fibrogenesis by erastin treatment. Conclusions: Our findings suggest that the DACH1/P53/SLC25A37 signaling pathway is a promising target for fibrotic disorders and reveals new regulatory mechanisms of ferroptosis.
- Open Access
- 6 September 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1193978
Cancer-associated fibroblasts in hematologic malignancies: elucidating roles and spotlighting therapeutic targets
Hematologic malignancies comprise a diverse range of blood, bone marrow, and organ-related disorders that present significant challenges due to drug resistance, relapse, and treatment failure. Cancer-associated fibroblasts (CAFs) represent a critical component of the tumor microenvironment (TME) and have recently emerged as potential therapeutic targets. In this comprehensive review, we summarize the latest findings on the roles of CAFs in various hematologic malignancies, including acute leukemia, multiple myeloma, chronic lymphocytic leukemia, myeloproliferative neoplasms, and lymphoma. We also explore their involvement in tumor progression, drug resistance, and the various signaling pathways implicated in their activation and function. While the underlying mechanisms and the existence of multiple CAF subtypes pose challenges, targeting CAFs and their associated pathways offers a promising avenue for the development of innovative treatments to improve patient outcomes in hematologic malignancies.
- 6 September 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1193978
Open AccessCancer-associated fibroblasts in hematologic malignancies: elucidating roles and spotlighting therapeutic targets
Hematologic malignancies comprise a diverse range of blood, bone marrow, and organ-related disorders that present significant challenges due to drug resistance, relapse, and treatment failure. Cancer-associated fibroblasts (CAFs) represent a critical component of the tumor microenvironment (TME) and have recently emerged as potential therapeutic targets. In this comprehensive review, we summarize the latest findings on the roles of CAFs in various hematologic malignancies, including acute leukemia, multiple myeloma, chronic lymphocytic leukemia, myeloproliferative neoplasms, and lymphoma. We also explore their involvement in tumor progression, drug resistance, and the various signaling pathways implicated in their activation and function. While the underlying mechanisms and the existence of multiple CAF subtypes pose challenges, targeting CAFs and their associated pathways offers a promising avenue for the development of innovative treatments to improve patient outcomes in hematologic malignancies.
- Open Access
- 1 May 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 2709-2723
Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case–control studies
Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case-control studies Qun Chen,1,2,* Hao Yuan,1,2,* Guo-Dong Shi,1,2,* Yang Wu,1–3 Dong-Fang Liu,1,2 Yu-Ting Lin,1,2 Lei Chen,1,2 Wan-Li Ge,1,2 Kuirong Jiang,1,2 Yi Miao1,2 1Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; 2Pancreas Institute, Nanjing Medical University, Nanjing, China; 3Division of Pancreatic Surgery, Department of General, Visceral, and Transplantation Surgery, Ludwig-Maximilians University, Munich, Germany *These authors contributed equally to this work Background: Previous studies have reported that nuclear receptor subfamily 5, group A, member 2 (NR5A2) polymorphisms (rs3790843 G>A, rs3790844 T>C, rs12029406 C>T) are associated with the risk of pancreatic cancer. However, the results of epidemiological investigations are still controversial. In order to explore its potential attributing factors, we pooled the updated literatures to evaluate the association between NR5A2 polymorphism and the risk of pancreatic cancer in this meta-analysis. Materials and methods: Databases such as PubMed, Google Scholar and China National Knowledge Infrastructure were searched for eligible articles following strict inclusion and exclusion criteria (updated to November 18, 2017). Odds ratios (ORs) and 95% CIs were computed to assess the intensity of association. In addition, heterogeneity, sensitivity analysis and publication bias were explored. All statistical analyses were conducted by STATA 14.0. Results: Our results showed that the rs3790843 (GA vs GG: OR=0.86, CI=0.76–0.98, P=0.992; GA+AA vs GG: OR=0.83, CI=0.73–0.94, P=0.950; A vs G: OR=0.85, CI=0.78–0.93, P=0.802), rs3790844 (CC vs TT: OR=0.65, CI=0.54–0.78, P=0.617; CC vs TT+CT: OR=0.73, CI=0.62–0.85, P=0.742; C vs T: OR=0.78, CI=0.73–0.84, P=0.555) and rs12029406 (TT vs CC: OR=0.73, CI=0.61–0.89, P=0.483; TT vs CC+CT: OR=0.78, CI=0.66–0.92, P=0.648; T vs C: OR=0.87, CI=0.79–0.95, P=0.837) polymorphisms were associated statistically with the risk of pancreatic cancer. Furthermore, the results of subgroup analysis showed that rs3790843 and rs3790844 polymorphisms were especially related to the risk of pancreatic cancer in Caucasian population. Conclusion: Our results revealed that NR5A2 may have a protective effect on pancreatic cancer. However, more well-designed researches are needed to verify the relationship between NR5A2 polymorphisms and the risk of pancreatic cancer. Keywords: NR5A2, polymorphism, rs3790844, pancreatic cancer, meta-analysis
- 1 May 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 2709-2723
Open AccessAssociation between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case–control studies
Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case-control studies Qun Chen,1,2,* Hao Yuan,1,2,* Guo-Dong Shi,1,2,* Yang Wu,1–3 Dong-Fang Liu,1,2 Yu-Ting Lin,1,2 Lei Chen,1,2 Wan-Li Ge,1,2 Kuirong Jiang,1,2 Yi Miao1,2 1Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; 2Pancreas Institute, Nanjing Medical University, Nanjing, China; 3Division of Pancreatic Surgery, Department of General, Visceral, and Transplantation Surgery, Ludwig-Maximilians University, Munich, Germany *These authors contributed equally to this work Background: Previous studies have reported that nuclear receptor subfamily 5, group A, member 2 (NR5A2) polymorphisms (rs3790843 G>A, rs3790844 T>C, rs12029406 C>T) are associated with the risk of pancreatic cancer. However, the results of epidemiological investigations are still controversial. In order to explore its potential attributing factors, we pooled the updated literatures to evaluate the association between NR5A2 polymorphism and the risk of pancreatic cancer in this meta-analysis. Materials and methods: Databases such as PubMed, Google Scholar and China National Knowledge Infrastructure were searched for eligible articles following strict inclusion and exclusion criteria (updated to November 18, 2017). Odds ratios (ORs) and 95% CIs were computed to assess the intensity of association. In addition, heterogeneity, sensitivity analysis and publication bias were explored. All statistical analyses were conducted by STATA 14.0. Results: Our results showed that the rs3790843 (GA vs GG: OR=0.86, CI=0.76–0.98, P=0.992; GA+AA vs GG: OR=0.83, CI=0.73–0.94, P=0.950; A vs G: OR=0.85, CI=0.78–0.93, P=0.802), rs3790844 (CC vs TT: OR=0.65, CI=0.54–0.78, P=0.617; CC vs TT+CT: OR=0.73, CI=0.62–0.85, P=0.742; C vs T: OR=0.78, CI=0.73–0.84, P=0.555) and rs12029406 (TT vs CC: OR=0.73, CI=0.61–0.89, P=0.483; TT vs CC+CT: OR=0.78, CI=0.66–0.92, P=0.648; T vs C: OR=0.87, CI=0.79–0.95, P=0.837) polymorphisms were associated statistically with the risk of pancreatic cancer. Furthermore, the results of subgroup analysis showed that rs3790843 and rs3790844 polymorphisms were especially related to the risk of pancreatic cancer in Caucasian population. Conclusion: Our results revealed that NR5A2 may have a protective effect on pancreatic cancer. However, more well-designed researches are needed to verify the relationship between NR5A2 polymorphisms and the risk of pancreatic cancer. Keywords: NR5A2, polymorphism, rs3790844, pancreatic cancer, meta-analysis
- Open Access
- 1 April 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 1801-1811
Association between WWOX and the risk of malignant tumor, especially among Asians: evidence from a meta-analysis
Purpose: Many studies have been carried out to examine whether there are associations between WWOX polymorphisms (rs3764340 C>G, rs12918952 G>A, and rs383362 G>T) and malignant tumor risk, but the results from these studies remained inconsistent and even controversial. In the present study, we performed a meta-analysis to evaluate the relationships comprehensively. Methods: Published reports were searched in PubMed, Google Scholar, and Chinese National Knowledge Infrastructure databases. Eight eligible case–control studies were included in the final analysis. In the analysis, pooled odds ratios (ORs) with corresponding 95% CIs were calculated in five genetic models to assess the genetic risk. Egger’s regression and Begg’s funnel plots test were conducted to appraise the publication bias. Results: We found that rs12918952 G>A and rs383362 G>T polymorphisms were not associated with the susceptibility of malignant tumor. However, a significant correlation was found between WWOX rs3764340 C>G and malignant tumor risk in three genetic models (CG vs CC: OR=1.31, 95% CI: 1.12–1.53, P=0.031; GG/CG vs CC: OR=1.31, 95% CI: 1.11–1.54, P=0.014; G vs C: OR=1.28, 95% CI: 1.09–1.50, P=0.009). Furthermore, when stratified by source of control, the results were significant especially in population-based control for rs3764340. Conclusion: In general, our results first indicated that the rs3764340 C>G polymorphism in WWOX gene can increase the susceptibility of tumor, while the others cannot. However, large, well-designed epidemiological studies are required to verify our findings.
- 1 April 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 1801-1811
Open AccessAssociation between WWOX and the risk of malignant tumor, especially among Asians: evidence from a meta-analysis
Purpose: Many studies have been carried out to examine whether there are associations between WWOX polymorphisms (rs3764340 C>G, rs12918952 G>A, and rs383362 G>T) and malignant tumor risk, but the results from these studies remained inconsistent and even controversial. In the present study, we performed a meta-analysis to evaluate the relationships comprehensively. Methods: Published reports were searched in PubMed, Google Scholar, and Chinese National Knowledge Infrastructure databases. Eight eligible case–control studies were included in the final analysis. In the analysis, pooled odds ratios (ORs) with corresponding 95% CIs were calculated in five genetic models to assess the genetic risk. Egger’s regression and Begg’s funnel plots test were conducted to appraise the publication bias. Results: We found that rs12918952 G>A and rs383362 G>T polymorphisms were not associated with the susceptibility of malignant tumor. However, a significant correlation was found between WWOX rs3764340 C>G and malignant tumor risk in three genetic models (CG vs CC: OR=1.31, 95% CI: 1.12–1.53, P=0.031; GG/CG vs CC: OR=1.31, 95% CI: 1.11–1.54, P=0.014; G vs C: OR=1.28, 95% CI: 1.09–1.50, P=0.009). Furthermore, when stratified by source of control, the results were significant especially in population-based control for rs3764340. Conclusion: In general, our results first indicated that the rs3764340 C>G polymorphism in WWOX gene can increase the susceptibility of tumor, while the others cannot. However, large, well-designed epidemiological studies are required to verify our findings.
- Retracted
- 4 December 2017
- Published by Wiley in International Journal of Cancer
- Vol. 142 (7) , 1392-1404
RETRACTED: YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway
Pancreatic ductal adenocarcinoma (PDAC) is one of the malignant lethal tumors. It has been reported that the transcriptional regulator Yin Yang‐1 (YY1) suppressed the invasion and metastasis of PDAC. However, the function of YY1 on proliferation and migration of pancreatic cancer remains to be clarified. In this study, we found that YY1 overexpression or knockdown can inhibit or promote the proliferation and migration of pancreatic cancer cells. Digital gene expression sequencing indicates that cyclin‐dependent kinase inhibitor 3 (CDKN3) may be the candidate target gene of YY1. Then we found that YY1 can downregulate the expression of CDKN3 by directly binding to the promoter region of CDKN3. Silencing CDKN3 expression could inhibit the ability of cell proliferation and migration and overexpression of CDKN3 could restore the effects induced by YY1 overexpression in pancreatic cancer cells. The expression levels of YY1 and CDKN3 were negatively correlated in pancreatic cancer tissues and PDAC patients with higher levels of CDKN3 have poor prognosis. Vitro and vivo study show that CDKN3 can form a complex with MdM2‐P53, thus leading to inhibiting the expression of P21, which is the target gene of P53, and finally facilitates the cell cycle to promote the proliferation of pancreatic cancer cells. Hence, YY1 can directly regulate the expression of CDKN3 and participate in the cycle of pancreatic cancer cells, which can inhibit the progression of pancreatic cancer. These results reveal that YY1‐CDKN3‐MDM2/P53‐P21 axis is involved in pancreatic tumorigenesis, which may develop new methods for human pancreatic cancer therapy.
- 4 December 2017
- Published by Wiley in International Journal of Cancer
- Vol. 142 (7) , 1392-1404
RetractedRETRACTED: YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway
Pancreatic ductal adenocarcinoma (PDAC) is one of the malignant lethal tumors. It has been reported that the transcriptional regulator Yin Yang‐1 (YY1) suppressed the invasion and metastasis of PDAC. However, the function of YY1 on proliferation and migration of pancreatic cancer remains to be clarified. In this study, we found that YY1 overexpression or knockdown can inhibit or promote the proliferation and migration of pancreatic cancer cells. Digital gene expression sequencing indicates that cyclin‐dependent kinase inhibitor 3 (CDKN3) may be the candidate target gene of YY1. Then we found that YY1 can downregulate the expression of CDKN3 by directly binding to the promoter region of CDKN3. Silencing CDKN3 expression could inhibit the ability of cell proliferation and migration and overexpression of CDKN3 could restore the effects induced by YY1 overexpression in pancreatic cancer cells. The expression levels of YY1 and CDKN3 were negatively correlated in pancreatic cancer tissues and PDAC patients with higher levels of CDKN3 have poor prognosis. Vitro and vivo study show that CDKN3 can form a complex with MdM2‐P53, thus leading to inhibiting the expression of P21, which is the target gene of P53, and finally facilitates the cell cycle to promote the proliferation of pancreatic cancer cells. Hence, YY1 can directly regulate the expression of CDKN3 and participate in the cycle of pancreatic cancer cells, which can inhibit the progression of pancreatic cancer. These results reveal that YY1‐CDKN3‐MDM2/P53‐P21 axis is involved in pancreatic tumorigenesis, which may develop new methods for human pancreatic cancer therapy.
- Open Access
- 2 December 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (67) , 110849-110860
A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Guodong Shi1, 2, *, Jingjing Zhang1, 2, *, Zipeng Lu1, 2, *, Dongfang Liu1, 2, *, Yang Wu1, 2, Pengfei Wu1, 2, Jie Yin1, 2, Hao Yuan1, 2, Qicong Zhu1, 2, Lei Chen1, 2, Yue Fu1, 2, Yunpeng Peng1, 2, Yan Wang3, Kuirong Jiang1, 2 and Yi Miao1, 2 1Pancreas Center, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China 2Pancreas Institute of Nanjing Medical University, Nanjing 210029, China 3Endoscopy Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China *These authors contributed equally to this work Correspondence to: Kuirong Jiang, email: jiangkuirongnjmu@sina.com Yi Miao, email: miaoyi@njmu.edu.cn Keywords: predictive signature; biomarker; bioinformatics; pancreatic ductal adenocarcinoma; relapse-free survival Received: June 16, 2017 Accepted: November 04, 2017 Published: December 02, 2017 ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) death rate and recurrence rate have remained obstinately high. Current methods can not satisfy the need of predicting cancer relapse accurately. Utilizing expression profiles of 10 GEO datasets (N = 774), we identified 154 differentially expressed genes (DEGs) between PDAC and normal pancreas tissue or paracancerous tissue. Next we built a 16-mRNA-based signature by means of the LASSO COX regression model. We also validated the prognostic value of the signature. Patients were classified into high-risk and low-risk group according to the signature risk score. 1 year RFS was 45% (95% CI: 31.6%–63.9%) for high-risk group in contrast to 92.5% (95% CI: 86.3%–99.1%)for low-risk group. Moreover, it could predict RFS well in cases with the receipt of different treatment modalities. The 16-mRNA-based signature was an independent and powerful prognostic biomarker for RFS for PDAC patients (HR = 7.74, 95% CI: 3.25–18.45, p < 0.0001).
- 2 December 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (67) , 110849-110860
Open AccessA novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Guodong Shi1, 2, *, Jingjing Zhang1, 2, *, Zipeng Lu1, 2, *, Dongfang Liu1, 2, *, Yang Wu1, 2, Pengfei Wu1, 2, Jie Yin1, 2, Hao Yuan1, 2, Qicong Zhu1, 2, Lei Chen1, 2, Yue Fu1, 2, Yunpeng Peng1, 2, Yan Wang3, Kuirong Jiang1, 2 and Yi Miao1, 2 1Pancreas Center, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China 2Pancreas Institute of Nanjing Medical University, Nanjing 210029, China 3Endoscopy Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China *These authors contributed equally to this work Correspondence to: Kuirong Jiang, email: jiangkuirongnjmu@sina.com Yi Miao, email: miaoyi@njmu.edu.cn Keywords: predictive signature; biomarker; bioinformatics; pancreatic ductal adenocarcinoma; relapse-free survival Received: June 16, 2017 Accepted: November 04, 2017 Published: December 02, 2017 ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) death rate and recurrence rate have remained obstinately high. Current methods can not satisfy the need of predicting cancer relapse accurately. Utilizing expression profiles of 10 GEO datasets (N = 774), we identified 154 differentially expressed genes (DEGs) between PDAC and normal pancreas tissue or paracancerous tissue. Next we built a 16-mRNA-based signature by means of the LASSO COX regression model. We also validated the prognostic value of the signature. Patients were classified into high-risk and low-risk group according to the signature risk score. 1 year RFS was 45% (95% CI: 31.6%–63.9%) for high-risk group in contrast to 92.5% (95% CI: 86.3%–99.1%)for low-risk group. Moreover, it could predict RFS well in cases with the receipt of different treatment modalities. The 16-mRNA-based signature was an independent and powerful prognostic biomarker for RFS for PDAC patients (HR = 7.74, 95% CI: 3.25–18.45, p < 0.0001).